Valeant hepatitis C drug misses goal, shares dive (Hepatitis C Infection)

Valeant hepatitis C drug misses goal, shares dive
Reuters - Mar 21, 2006... Valeant Pharmaceuticals International (VRX.N: Quote, Profile, Research) said on Tuesday a late-stage trial showed its chronic hepatitis C treatment was not as ...

Cuban Combined Therapy Against Chronic Hepatitis C
Ahora.cu, Cuba - Mar 23, 2006A Cuban combination therapy for the treatment of chronic Hepatitis C is to be put on the market by the Heber Biotec SA company in Latin America, Asia, Africa ...

(PRN) - Demographic Study Finds the Digital Divide is Closing ... ...
Bolsamania.com, Spain - Mar 14, 2006... Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin In Treatment-Experienced Patients With Chronic Hepatitis C ...

Novelos Therapeutics Closes $15 Million Private Placement
International News Service, Australia - Mar 7, 2006... NOV-002 in lung cancer, in addition to our other clinical development programs, including chemotherapy-resistant ovarian cancer and chronic hepatitis C with NOV ...

Human Genome Sciences up on drug outlook
BusinessWeek - Mar 1, 2006... on Wednesday after the company presented at an investor conference and provided an "upbeat" outlook for Albuferon, a possible treatment for chronic hepatitis C ...

Hepatitis C Infection - VX-950 To Get Fast Tracked

VX-950 To Get Fast Tracked
As you may recall we've been saying VX-950 is the revolutionary new therapy to watch for HCV. Now it looks like the FDA agrees this treatment is quite promising and deserving of faster approval than a lesser worthy approach. Another...

Share and Discover Hepatitis C from Anywhere.
Add Hepatitis C to your Google Toolbar to Share and Discover Hepatitis C from Anywhere.

Alcoholism Facts
Title: Alcoholism FactsCategory: Health FactsCreated: 8/9/2005Last Editorial Review: 8/29/2005

Hepatitis B
Title: Hepatitis BCategory: Diseases and ConditionsCreated: 1/26/2001 11:58:00 AMLast Editorial Review: 9/21/2005

Hepatitis C Epidemic Vastly Underestimated By UK Government (Hepatitis C Infection)

Hepatitis C Epidemic Vastly Underestimated By UK Government
Medical News Today - There are more than double the number of people infected with the hepatitis C virus (HCV) in England and Wales than the government has estimated, delegates at the British Society of Gastroenterology's Annual Scientific Meeting were warned. The

Novartis Seen 'Saving Face' With Idenix Hep C Deal
Forbes - Friedman, Billings, Ramsey reiterated an "outperform" rating on Idenix Pharmaceuticals after Swiss pharmaceutical titan Novartis exercised an option to co-develop the biotech firm's lead drug candidate. Novartis (nyse: NVS - news - people ) will pay

Tata may make Rs 1 lakh car in Jamshedpur
Financial Express - JAMSHEDPUR, MARCH 28: Tata Motors may choose to produce its Rs 1 lakh car in Jamshedpur. It is at a preliminary stage. They have their expansion plan for Jamshedpur. We are discussing that (Rs 1 lakh car project), said a senior bureaucrat from

Aethlon Medical and Commonwealth Biotechnologies Sign Cooperative
Genetic Engineering News - Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has signed a cooperative research agreement with Commonwealth Biotechnologies, Inc. (CBI). Under the agreement, Aethlon

Valeant Pharmaceuticals
Forbes - ThinkEquity Partners reiterated a "sell" rating on Valeant Pharmaceuticals International after the drugmaker announced disappointing results for experimental hepatitis C drug Viramidine. Valeant (nyse: VRX - news - people ) said early Tuesday that

Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to

Home Access (Hepatitis C Infection) Hepatitis C Check Kit, an at-home test for detecting Hepatitis C virus

Home Access Hepatitis C Check Kit, an at-home test for detecting Hepatitis C virus
... judgment and can contribute to exposure to Hepatitis C infection. Any shared drug products or equipment (i ... prevent or reduce exposure to Hepatitis C infection? A: The best way ...

Hepatitis C Virus, HCV Virus Infection, Hepatitis C Virus Infection
This page contains notes on hepatitis C virus. ... sometimes associated with chronic hepatitis C infection. eg. mixed cryoglobulinaemia, membranoproliferative ... of the epidemiology of hepatitis C infection. The efficacy of ...

P4042 If you have hepatitis C, which vaccinations do you need?
P4042 This chart is for patients, and shows which vaccinations one needs if they have hepatitis C.

All About Hepatitis C- Hepatitis C causes, symptoms, testing, and treatments
Learn more about Hepatitis C, a liver disease caused by the hepatitis c virus (HCV), symptoms, testing and treatments. ... Each year, there are about 35,000 new cases of hepatitis C infection ... In the majority of cases, however, the hepatitis C infection becomes chronic (that is, it lasts for ...

Hepatitis C Infection - Hepatitis C: Fact Sheet | CDC Viral Hepatitis

Hepatitis C: Fact Sheet | CDC Viral Hepatitis
There is no vaccine to prevent hepatitis C. Do not shoot drugs; ... Hepatitis C. HCV positive persons should be evaluated by their doctor for liver disease. ...

MedlinePlus Medical Encyclopedia: Hepatitis C
Hepatitis C infection is caused by hepatitis C virus (HCV). Persons who may be at risk for hepatitis C are those who:. Received a blood transfusion prior to ...

VA National Hepatitis C Program
The Veterans Affairs National Hepatitis C Web site provides information about viral hepatitis for health care providers inside and outside the VA system, ...

HEPATITIS C INFO CENTER - With Daily Hepatitis C Updates
Find all the Hepatitis C information you are looking for, over 2500 pages, INCLUDING THE LATEST NEWS about infection, symptoms and treatment...

Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C (Hepatitis C Infection) Compounds

Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C Compounds
[Press Release] PR Newswire via Yahoo! Finance - Mar 20 5:30 AM
Schering-Plough Corporation and PTC Therapeutics, Inc. today announced that they have entered into an exclusive collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus infection and other viral diseases.Save to My Web

Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 5:30 AM
Coley Pharmaceutical Group, Inc. today announced positive top-line interim data from the company's twelve-week, randomized, controlled clinical study of Actilon in combinations with pegylated interferon and/or ribavirin for the treatment of chronic Hepatitis C virus in the relapsed subset of treatment experienced patients.Save to My Web

Novelos Therapeutics files IND for new hepatitis C drug
BizJournals - Mar 22 8:23 AM
Novelos Therapeutics Inc., a Newton-based biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for NOV-205, its second clinical stage compound.Save to My Web

euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year
vwd.de - Mar 05 10:43 PM
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.Save to My Web

Novelos Therapeutics Announces $15 Million Private Placement, Supplementing Today's Earlier Announcement
[Press Release] Business Wire via Yahoo! Finance - Mar 02 4:12 PM
NEWTON, Mass.----March 2, 2006--Novelos Therapeutics, Inc. , a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has entered into definitive securities purchase agreements with institutional investors to raise $15.06 million in gross proceeds through the sale of shares of its common stock and warrants.Save to My Web